Login to Your Account

Aria happy now? Madrigal proves Synta merger smart

By Randy Osborne
Staff Writer

Wednesday, December 6, 2017

Madrigal Pharmaceuticals Inc. is waiting on further data to provide firm guidance about a potential phase III trial, but shares meanwhile soared 88.3 percent, or $40.88, to close Wednesday at $87.18 on word of positive top-line findings.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription